This is the authors' abstract. We don't add key points for this paper.
Hepatic lipid homeostasis is controlled by multiple processes, including VLDL-TG secretion. We have previously shown that the FLCN/TFE3 branch of mTORC1 signaling controls hepatic fatty acid oxidation and de novo lipogenesis to protect mice from MAFLD. We now show that the FLCN/TFE3 pathway also controls VLDL-TG secretion via direct transcriptional activation of a broad program of genes involved in VLDL-TG secretion, including PCYT1A, the rate-limiting step of phosphatidylcholine synthesis. Loss of hepatic FLCN upregulates VLDL-TG secretion and prevents MAFLD, and this protection requires TFE3 and PCYT1A. The data unveil a new pathway that orchestrates multiple steps of VLDL-TG synthesis and secretion. The data also highlight that suppressing the selective FLCN/TFE3 branch of mTORC1 signaling maximizes hepatic lipid clearance by coordinately promoting fatty acid oxidation, suppressing de novo lipogenesis, and boosting VLDL-TG secretion, providing an attractive therapeutic target for the treatment of MAFLD.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Thorsheim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: